Bacterial vaginosis – a recurring problem
Today bacterial vaginosis is usually treated with antibiotics, which is often a short-term solution. This is because the antibiotics kill the infection, but at the same time destroy some of the important protective bacteria in the vaginal bacterial flora.
Consequently, for around half of all those treated for bacterial vaginosis with antibiotics, the infection reappears within 90 days.
Another common side effect of antibiotic treatment is fungal infections, which also affect approx. 50% of treated patients.
The prevalence of bacterial vaginosis is currently 10-30%. Moreover, there is limited access to gynaecologists and doctors. pHyph is expected to prevent new infections and will be an easily accessible over-the-counter option for anyone suffering from bacterial vaginosis.
The vaginal microbiome comprises bacteria that protect the body against infections. When something happens to cause an imbalance in these bacteria, bacterial vaginosis can develop. Vaginal infections are stressful, both mentally and physically. Symptoms of bacterial vaginosis can be painful; vaginal discomfort, a burning sensation and an unpleasant odour. The infection therefore brings the risk of a major negative impact on a woman’s daily life, particularly in the case of recurrent infections.
We have reason to believe that pHyph helps to restore the vaginal microbiome and so significantly reduces the risk of recurrent bacterial infections.
A total of 75% are over-the-counter products without scientifically proven effect.2
According to the World Health Organization (WHO), antibiotic resistance is one of the greatest threats to global health of our time
The use of antibiotics gives rise, sooner or later, to antibiotic resistance. Reduced use of antibiotics may at least help to delay resistance emergence. One of the most important future changes we can make is to reduce the use of antibiotics, and there is considerable demand for sustainable treatment options with an equivalent effect, without the risk of either resistance or antibiotic-related side effects.
A total of 4% of all antibiotics prescribed to women in Sweden are used to treat bacterial vaginosis. Of all antibiotic prescriptions in Sweden, 2.4% are issued for the same indication.1
1.Socialstyrelsen’s (the Swedish National Board of Health and Welfare) pharmaceutical database 2019.
In Europe alone approx. 15-45 million women annually suffer an infection.
Among women the world over, the need for an effective and easily accessible treatment is immense – and there is currently no antibiotic-free treatment that both prevents and cures.